The Asia Pacific Telmisartan Market is expected to witness market growth of 7.2% CAGR during the forecast period (2020-2026).
Telmisartan is considered as a prescription medication, which is frequently suggested to ease down and broaden blood vessels in persons having elevated blood pressure. Telmisartan means a set of drugs called as angiotensin II receptor blockers (ARBs). Telmisartan could be utilized alone or in combination with other medications like hydrochlorothiazide with an aim to treat elevated blood pressure.
The growth of the Telmisartan market is expected to be supplemented by the increasing number of supportive government policies for hypertension management. For example, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) introduced, ‘India Hypertension Management Initiative (IHMI)’. The IHMI focuses to decrease death & disability associated with cardiovascular disease (CVD), by enhancing control over elevated blood pressure (hypertension), lowering down salt consumption from food, and cutting down artificial trans-fats, which are supporting the risks for creating CVD.
The Hypertension market dominated the Malaysia Telmisartan Market by Indication in 2019, thereby, achieving a market value of $45.1 million by 2026. The Cardiovascular Risk Reduction market is expected to witness a CAGR of 9% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments covered in the Report:
By Indication
By Distribution Channel
By Country
Companies Profiled
Unique Offerings from the Publisher
Telmisartan is considered as a prescription medication, which is frequently suggested to ease down and broaden blood vessels in persons having elevated blood pressure. Telmisartan means a set of drugs called as angiotensin II receptor blockers (ARBs). Telmisartan could be utilized alone or in combination with other medications like hydrochlorothiazide with an aim to treat elevated blood pressure.
The growth of the Telmisartan market is expected to be supplemented by the increasing number of supportive government policies for hypertension management. For example, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) introduced, ‘India Hypertension Management Initiative (IHMI)’. The IHMI focuses to decrease death & disability associated with cardiovascular disease (CVD), by enhancing control over elevated blood pressure (hypertension), lowering down salt consumption from food, and cutting down artificial trans-fats, which are supporting the risks for creating CVD.
The Hypertension market dominated the Malaysia Telmisartan Market by Indication in 2019, thereby, achieving a market value of $45.1 million by 2026. The Cardiovascular Risk Reduction market is expected to witness a CAGR of 9% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments covered in the Report:
By Indication
- Hypertension
- Cardiovascular Risk Reduction
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Telmisartan Market by Indication
Chapter 4. Asia Pacific Telmisartan Market by Distribution Channel
Chapter 5. Asia Pacific Telmisartan Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Methodology
LOADING...